• INCYTON GmbH
  • Am Klopferspitz 19
  • 82152 Planegg/Martinsried
  • Germany
  • moc.notycni@ofni

Dr. Martin Strehle, CEO

About INCYTON

INCYTON® is a privately financed company which automizes and optimizes cell-based assays by combining precise sensorics for cellular key parameters with subsequent attuned actuator technology. Our multi-sensor systems monitor different key parameters simultaneously, in real-time and label-free. Thanks to our technology every event will be recorded giving the user full control on every time-point without being constantly present. INCYTON® smart technology is combined in one housing, creating a global environmental control for all processes and reducing variations due to human influence. Having an incubator together with the measuring devices and treatment station reduces the risk of contamination and increases the safety of lab workers while dealing with dangerous substances and pathogens.

What is your motivation?

We as INCYTON® constantly strive for new horizons in the field of cell-based analysis. Experience and innovation help us to continuously increase the achievable information content in each experiment. Customers and employees are our top priority. By working together, and through the development of suitable measuring systems and software solutions, we aim for a comprehensive and complete understanding of global cellular reactions.  Thus, we focus on label-free in vitro monitoring with microfluidic flow and fully controllable ambient conditions. We engage in future-oriented research through our entirely “made in Germany” solutions. Thanks to the smart combination of actuators and life-science sensor technology, we increase the efficiency of the experiment of our customers. Our intent is to improve the prediction of the effects of active substances, drugs and drug candidates in various cell lines already in the less cost intensive preclinical phase as well as in regulatory validation studies.

“Due to its resident companies, IZB offers an ideal mixture of relevant networks, outstanding events, and international recognition, which is particularly beneficial for start-ups.”

Dr. Martin Strehle, CEO

INCYTON GmbH is a privately financed company which automizes and optimizes cell-based assays by combining precise sensorics for cellular key parameters with therefore attuned actuator technology. Through the development of suitable measuring systems and software solutions we aim a comprehensive and complete understanding of global cellular reactions. Therefore, we focus on label-free in vitro monitoring under microfluidic and completely controllable ambient conditions. Our intent is to improve the prediction of the effects of active substances, drugs and drug candidates in various cell lines already in the less cost intensive preclinical phase as well as in regulatory validation studies.